id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-269151-r426u5dz	Turner, Jeffrey M.	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?	2020-07-09		.txt	text/plain	4596	173	37	The CHARM-alternative trial, which compared candesartan to placebo in patients with HFrEF who were intolerant to ACE inhibitors, reported a significant reduction in cardiovascular mortality, CHF hospitalizations, and all-cause mortality similar to those seen with previous ACE inhibitor trials [15] . Both European and American guidelines state that ARB therapy in heart failure with reduced ejection fraction (HFrEF) should be reserved for those who are either intolerant of ACE inhibitors or who remain symptomatic despite ACE inhibitor therapy, and in the latter scenario, subjects with HFrEF should be treated with an ARB in the form of an angiotensin receptor neprilysin inhibitor	cache/cord-269151-r426u5dz.txt	txt/cord-269151-r426u5dz.txt
